Targeting Solid Tumors Using CD3 Bispecific Antibodies

Immunotherapies to treat cancer have made tremendous progress over the past decade. In particular, T cell-directed therapies have gained considerable attention with CD3 bispecific antibodies and CAR T cells showing potent responses against hematologic tumors. At present, the ability to adapt these therapeutics to treat solid tumors is less established. Herein, we discuss recent advances in T cell-engaging CD3 bispecific antibodies targeting solid tumors, potential mechanisms of resistance, and future prospects. A better understanding of the mechanisms of immune evasion in solid tumors will enable the development of strategies to overcome this resistance and inform choices of therapeutic combinations.

Automated summary

Immunotherapies for cancer treatment have progressed significantly in the past decade, with a focus on T cell-directed therapies such as CD3 bispecific antibodies and CAR T cells. However, the application of these therapies to solid tumors remains a challenge, with ongoing research needed to overcome resistance mechanisms.